Enrolling Now: ExoLuminate Study

Biological Dynamics has developed an early diagnostic detection test utlizing AC Electrokinetics (ACE) to isolate exosomes from blood, which studies show can identify pancreatic cancer as early as Stage 1.

Are you at risk?

Learn more about the clinical study for those at risk for developing pancreatic cancer. You have the power to help change how we treat this devastating disease.

LATEST PUBLICATIONS
Development of a blood-based extracellular vesicle classifier for detection of early-stage pancreatic ductal adenocarcinoma
Enhancement of dielectrophoresis-based particle collection from high conducting fluids due to partial electrode insulation
Case Report: Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy
On‐chip dielectrophoretic recovery and detection of a lactate sensing probiotic from model human saliva
cyc‐DEP: Cyclic immunofluorescence profiling of particles collected using dielectrophoresis
Theoretical and experimental analysis of negative dielectrophoresis‐induced particle trajectories
Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test
Automated fluorescence quantification of extracellular vesicles collected from blood plasma using dielectrophoresis
Simultaneous Isolation of Circulating Nucleic Acids and EV-associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform
Plasma Biomarker for Post-concussive Syndrome: A Pilot Study Using an Alternating Current Electro-Kinetic Platform

LATEST NEWS

Featured
Press Release
Biological Dynamics Announces Expanding Adoption of ExoVerita™ Pro Under Early Access Program
Press Release

Biological Dynamics, Inc., a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform. ExoVerita Pro supports exosome-based research efforts, helping to accelerate early disease detection, determine therapeutic response, and more.

Read More →
Press Release
Press Release
Leading Academic Medical Centers Join Biological Dynamics’ ExoLuminate™ Study, Expanding Enrollment for Early Pancreatic Cancer Detection
Press Release

Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown. 

Read More →
Press Release